Therapeutic Antibodies Europe
13-14 October, 2010
London, UK

Europe’s most respected biopharmaceutical executives at Therapeutic Antibodies Europe

• The therapeutic antibodies Europe Conference are addressing monoclonal antibody trends, topical authorization successes and clinical updates.
• Case studies to show the most recent antibody improvements
• Representation from the most important pharmaceutical and biotech companies in the antibody market

Conference Background:

Antibodies are highly specific, biologically evolved molecules that recognize and eradicate pathogenic and disease antigens. During the last 30 years antibody research has come a long way but the development of new multipurpose therapeutic agents to fight cancer, autoimmune diseases and infections is costly and time intensive.

Technology developments and the testing of new antibody reagents generations have changed our view of how they might be employed for prophylactic and therapeutic purposes.

Today’s therapeutic antibodies are genetically engineered molecules that are designed to guarantee high specificity and functionality. Some are laden with toxic modules, whereas others are designed to function naturally. But, the industry is more competitive than ever before and thousands of biotech companies, contract antibody providers are fighting to stay on top of the game.

At Therapeutic Antibodies Europe you will learn about the latest technological developments, testing issues and the engineering of tomorrow’s antibody generations. Meet and discuss with the leading experts of the antibody market to set your company’s strategy straight and be able to stay competitive.